Skip to main content
Grant Details

Grant Number: 5R03CA115225-02 Interpret this number
Primary Investigator: Mulvihill, Sean
Organization: University Of Utah
Project Title: Novel Serum Markers for Pancreatic Adenocarcinoma
Fiscal Year: 2006
Back to top


Abstract

DESCRIPTION (provided by applicant): Adenocarcinoma of the pancreas is the fifth most common cause of cancer deaths in both men and women in the United States. The 5-year survival rate is about 4%, which is the lowest of any cancer. Recent advances in proteomic research have led to the discovery of disease-related proteins that circulate in the blood. Such proteins may provide a non-invasive means for detecting and monitoring cancer. Novel biomarkers for pancreatic adenocarcinoma are needed since currently available markers have limited clinical utility. The most widely used pancreatic tumor marker, CA 19-9, has high variability and is often undetectable in serum of patients with small tumors. Two proteins, haptoglobin and serum amyloid A, have been detected in the serum of patients with various cancers as well as a mouse model of pancreatic cancer. However, these proteins have not been adequately evaluated in humans with pancreatic adenocarcinoma. The goal of this project is to investigate the potential clinical utility of haptoglobin and serum amyloid A for detecting pancreatic adenocarcinoma. Specifically, we intend to determine if serum levels of these proteins are significantly elevated in patients with pathologically verified disease, determine if serum levels correlate with measures of tumor severity, and assess the relative accuracy for haptoglobin, serum amyloid A and CA 19-9 in distinguishing those patients with pancreatic adenocarcinoma from age and gender matched controls. In this study's second phase, we will use serum levels of haptoglobin and serum amyloid A to evaluate members of families identified through the Utah Population Database to be at high risk for pancreatic cancer. This work has direct health-related significance in identifying improved screening tests for pancreatic cancer.

Back to top


Publications

Surgical overtreatment of pancreatic intraductal papillary mucinous neoplasms: Do the 2017 International Consensus Guidelines improve clinical decision making?
Authors: Sharib J.M. , Fonseca A.L. , Swords D.S. , Jaradeh K. , Bracci P.M. , Firpo M.A. , Hatcher S. , Scaife C.L. , Wang H. , Kim G.E. , et al. .
Source: Surgery, 2018 12; 164(6), p. 1178-1184.
EPub date: 2018-08-28.
PMID: 30170819
Related Citations

Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer.
Authors: Kendrick Z.W. , Firpo M.A. , Repko R.C. , Scaife C.L. , Adler D.G. , Boucher K.M. , Mulvihill S.J. .
Source: HPB : the official journal of the International Hepato Pancreato Biliary Association, 2014 Jul; 16(7), p. 670-6.
EPub date: 2013-12-06.
PMID: 24308545
Related Citations

Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.
Authors: Poruk K.E. , Firpo M.A. , Scaife C.L. , Adler D.G. , Emerson L.L. , Boucher K.M. , Mulvihill S.J. .
Source: Pancreas, 2013 Mar; 42(2), p. 193-7.
PMID: 23407481
Related Citations

The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.
Authors: Poruk K.E. , Gay D.Z. , Brown K. , Mulvihill J.D. , Boucher K.M. , Scaife C.L. , Firpo M.A. , Mulvihill S.J. .
Source: Current molecular medicine, 2013 Mar; 13(3), p. 340-51.
PMID: 23331006
Related Citations

Screening for pancreatic cancer: why, how, and who?
Authors: Poruk K.E. , Firpo M.A. , Adler D.G. , Mulvihill S.J. .
Source: Annals of surgery, 2013 Jan; 257(1), p. 17-26.
PMID: 22895395
Related Citations

Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression.
Authors: Fukuda A. , Wang S.C. , Morris J.P. , Folias A.E. , Liou A. , Kim G.E. , Akira S. , Boucher K.M. , Firpo M.A. , Mulvihill S.J. , et al. .
Source: Cancer cell, 2011-04-12; 19(4), p. 441-55.
PMID: 21481787
Related Citations

Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma.
Authors: Poruk K.E. , Firpo M.A. , Huerter L.M. , Scaife C.L. , Emerson L.L. , Boucher K.M. , Jones K.A. , Mulvihill S.J. .
Source: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2010 Oct; 19(10), p. 2605-10.
EPub date: 2010-08-20.
PMID: 20729288
Related Citations

Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen.
Authors: Firpo M.A. , Gay D.Z. , Granger S.R. , Scaife C.L. , DiSario J.A. , Boucher K.M. , Mulvihill S.J. .
Source: World journal of surgery, 2009 Apr; 33(4), p. 716-22.
PMID: 19082654
Related Citations




Back to Top